No abstract

No abstract

No abstract

(2E)-3-(2-Bromo-6-hydroxy-4-methoxyphenyl)-1-(naphthalene-2-yl)prop-2-en-1-one (d1) was synthesized by the Claisen-Schmidt condensation method and characterized by 1H NMR, 13C NMR spectral studies. The anti-inflammatory activity was conducted in Swiss albino rats for paw edema model. Edema was actuated with 1 % carrageenan to every one of the animals following 1 h of the oral medicines. Paw thickness was checked at t = 1, 2, 3, 4, 5 and 24 h. Stair climbing score and motility score were surveyed at t = 24 h. Compound d1 signicant decline in paw thickness at p < 0.001 diminished by 32 % in paw thickness. The compound d1 signicantly expanded the stair climbing and motility score. This study suggested that the compound d1 exhibits remarkable anti-inflammatory activity when compared with that of the standard drug.